Imipenem/relebactam pharmacokinetics in critically ill patients supported on extracorporeal membrane oxygenation.
Andrew J FratoniAbigail K KoisJason A GluckDavid P NicolauJoseph L KutiPublished in: The Journal of antimicrobial chemotherapy (2024)
Imipenem/cilastatin/relebactam dosed according to package insert in patients supported on ECMO is predicted to achieve exposures sufficient to treat susceptible Gram-negative isolates, including Pseudomonas aeruginosa.
Keyphrases
- extracorporeal membrane oxygenation
- gram negative
- acute respiratory distress syndrome
- pseudomonas aeruginosa
- end stage renal disease
- multidrug resistant
- respiratory failure
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cystic fibrosis
- peritoneal dialysis
- prognostic factors
- air pollution
- mechanical ventilation
- escherichia coli
- patient reported outcomes
- drug resistant
- biofilm formation
- patient reported
- genetic diversity
- staphylococcus aureus